Long-term follow-up of acute partial transverse myelitis

Archives of Neurology

Volumn 69, Issue 3, 2012, Pages 357-362

  Bourre, Bertrand ^a   Zéphir, Hélène ^c   Ongagna, Jean Claude ^d   Cordonnier, Charlotte ^c   Collongues, Nicolas ^d,e   Debette, Stephanie ^c   Fleury, Marie Celine ^d   Outerryck, Olivier ^c   Hannequin, Didier ^a,b   Vermersch, Patrick ^c   De Seze, Jerome ^d  

^a HÔPITAL CHARLES NICOLLE   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

^d HÔPITAL CIVIL   (France)

^e Université de Strasbourg Faculté de Psychologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; OLIGOCLONAL BAND;

ACUTE PARTIAL TRANSVERSE MYELITIS; AGE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; DISEASE CLASSIFICATION; EVOKED VISUAL RESPONSE; EXPANDED DISABILITY STATUS SCALE SCORE; FEMALE; FOLLOW UP; FRANCE; HOSPITAL DEPARTMENT; HUMAN; LILLE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; POSTINFECTIOUS MYELITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; ROUEN; SCORING SYSTEM; SEX RATIO; SJOEGREN SYNDROME; STRASBOURG;

ADOLESCENT; ADULT; AGED; BRAIN; DISABILITY EVALUATION; DISEASE PROGRESSION; EVOKED POTENTIALS, VISUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELITIS, TRANSVERSE; NEUROLOGIC EXAMINATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK; SPINAL CORD; SPINAL PUNCTURE; YOUNG ADULT;

EID: 84858604023     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.949     Document Type: Article

References (19)

1. Kappos L, Freedman MS, Polman CH, et al BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389-397. (Pubitemid 47189673)
2. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346(3):158-164. (Pubitemid 34438881)
3. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131 (pt 3):808-817. (Pubitemid 351294716)
4. Tintoré M, Rovira A, Río J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology. 2006;67(6):968-972. (Pubitemid 44454586)
5. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65(6):727-732.
6. Bruna J, Martínez-Yélamos S, Martínez-Yélamos A, Rubio F, Arbizu T. Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler. 2006;12(2):169-173.
7. Cordonnier C, de Seze J, Breteau G, et al. Prospective study of patients presenting with acute partial transverse myelopathy. J Neurol. 2003;250(12):1447- 1452.
8. Harzheim M, Schlegel U, Urbach H, Klockgether T, Schmidt S. Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients. J Neurol Sci. 2004;217(2):217-223. (Pubitemid 38056558)
9. Scott TF, Kassab SL, Singh S. Acute partial transverse myelitis with normal cerebral magnetic resonance imaging: transition rate to clinically definite multiple sclerosis. Mult Scler. 2005;11(4):373-377. (Pubitemid 40984228)
10. Sellner J, Lüthi N, Bühler R, et al. Acute partial transverse myelitis: risk factors for conversion to multiple sclerosis. Eur J Neurol. 2008;15(4):398-405. (Pubitemid 351422397)
11. Ford B, Tampieri D, Francis G. Long-term follow-up of acute partial transverse myelopathy. Neurology. 1992;42(1):250-252.
12. de Seze J, Stojkovic T, Breteau G, et al. Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases. Brain. 2001;124(pt 8):1509-1521. (Pubitemid 32726765)
13. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. (Pubitemid 14237132)
15. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997; 120(pt 11):2059-2069. (Pubitemid 27493740)
16. Jacobs LD, Beck RW, Simon JH, et al CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343(13):898-904.
17. Schneider R, Euler B, Rauer S. Intrathecal IgM-synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event. Eur J Neurol. 2007;14(8):907-911. (Pubitemid 47106779)
18. Mandrioli J, Sola P, Bedin R, Gambini M, Merelli E. A multifactorial prognostic index in multiple sclerosis: cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol. 2008;255(7):1023-1031.
19. Villar LM, Masjuan J, González-Porqué P, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology. 2002;59(4):555-559. (Pubitemid 34919989)